TAIPEI and SAN DIEGO, Dec. 23, 2025 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a clinical-stage company developing first-in-class therapeutics for oncology, rare diseases and infectious diseases, outlined progress across its AI-enabled drug development platform at its 2025 annual investor conference, saying it is positioning itself for a period of generational change in immuno-oncology.
With several blockbuster immune-oncology drugs facing major patent expirations before 2030, pharmaceutical companies are pursuing next-generation assets that can be combined across multiple tumor types. Senhwa described an integrated strategy that combines artificial intelligence validation, precision clinical development and global pharmaceutical partnerships to meet that demand.
Senhwa said Google DeepMind applied its C2S-Scale biological AI model to more than 4,000 drug candidates and identified Silmitasertib (CX-4945) as a leading candidate to restore anti-tumor immune activity. The analysis, supported by Google’s computing infrastructure and preclinical validation conducted by Yale University, found that CX-4945 enhances tumor antigen presentation, a key mechanism for improving immune recognition of cancer cells.
The company called the independent validation a milestone for applying AI to oncology drug discovery and said CX-4945 may address the challenge of immunologically “cold” tumors that have shown limited response to immunotherapy.
Senhwa also announced a clinical collaboration with BeOne Medicines to evaluate Pidnarulex (CX-5461) in combination with BeOne’s approved PD-1 inhibitor tislelizumab. The initial program will focus on pancreatic cancer and other advanced solid tumors, including immunotherapy-resistant melanoma.
CX-5461 is described by Senhwa as a first-in-class small molecule with a dual mechanism that stabilizes DNA G-quadruplex structures and inhibits RNA polymerase I. That activity induces replication stress in tumor cells and activates the innate cGAS–STING pathway, which the company says can convert immune-cold tumors into immune-active environments and improve responses to existing immunotherapies.
Senhwa said its pathway-level, multi-target strategy aims to position CX-5461 as a potential backbone for combination regimens across cancer types rather than as an indication-specific asset, a positioning that has attracted interest from multinational partners.
Near-term catalysts over the next one to three years include clinical data readouts for CX-5461 and CX-4945, expansion of global partnerships, potential licensing collaborations and increased visibility at major oncology conferences such as ASCO, AACR and ESMO.
“Senhwa has transitioned beyond early-stage discovery and development into a company building a scalable, AI-validated oncology platform,” the company said, adding that it is focused on advancing differentiated science to create long-term value for patients, partners and shareholders.
Leave a Reply